@article {8198,
	title = {Primary therapy of Waldenstr{\"o}m{\textquoteright}s macroglobulinemia with 2-chlorodeoxyadenosine},
	journal = {Journal of Clinical Oncology},
	volume = {12},
	year = {1994},
	note = {Cited By :111Export Date: 21 February 2017},
	month = {1994},
	pages = {2694 - 2698},
	abstract = {Purpose: To assess the activity of 2-chlorodeoxyadenosine (2CdA) as primary therapy for patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinemia. Patients and Methods: 2CdA was given to 26 consecutive, previously untreated and symptomatic patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinemia. Two courses were administered to outpatients at a dose of 0.1 mg/ kg body weight per day for a 7-day continuous infusion using a portable pump through a central venous catheter. Responding patients were followed up without further therapy and were scheduled to receive two additional treatments with 2CdA on disease relapse. Results: Twenty-two of 26 patients responded to the 2CdA therapy (85\%; 95\% confidence interval [Cl], 65\% to 96\%), including three patients who achieved a complete response and 19 patients who had a partial response. Treatment was well tolerated, with no acute hematologic toxicity. A marked and sustained reduction of CD4+ lymphocytes occurred in all patients and may have contributed to a fatal infection with disseminated herpes simplex in one patient. With a median follow-up of 13 months, five patients have relapsed and all re-treated patients have responded again to 2CdA. Conclusion: 2CdA is highly active in previously untreated patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinemia. A limited program of treatment induced responses of good quality and long duration in more than 80\% of patients. {\textcopyright} 1994 by American Society of Clinical Oncology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028173001\&partnerID=40\&md5=623e41ebed553144f5680076cf0a8cb9},
	author = {Dimopoulos, M.A. and Kantarjian, H. and Weber, D. and O{\textquoteright}Brien, S. and Estey, E. and Delasalle, K. and Rose, E. and Cabanillas, F. and Keating, M. and Alexanian, R.}
}
